SPDR S&P Pharmaceuticals ETF
XPH
XPH
68 hedge funds and large institutions have $128M invested in SPDR S&P Pharmaceuticals ETF in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 23 reducing their positions, and 9 closing their positions.
Holders
68
Holders Change
-4
Holders Change %
-5.56%
% of All Funds
0.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
18
Reduced
23
Closed
9
Calls
$569K
Puts
$1.14M
Net Calls
-$574K
Net Calls Change
+$303K
Top Buyers
| 1 |
1
Bank of America
Charlotte,
North Carolina
|
$30.7M |
| 2 |
2
Citigroup
New York
|
$11M |
| 3 |
3
Goldman Sachs
New York
|
$5.25M |
| 4 |
4
Rockefeller Capital Management
New York
|
$2.51M |
| 5 |
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
$4.03M |
Top Sellers
| 1 |
1
Morgan Stanley
New York
|
$21.9M |
| 2 |
2
BNP Paribas Financial Markets
Paris,
France
|
$1.81M |
| 3 |
3
Citadel Advisors
Miami,
Florida
|
$181K |
| 4 |
4
Royal Bank of Canada
Toronto,
Ontario, Canada
|
$1.2M |
| 5 |
5
LPL Financial
San Diego,
California
|
$4.83M |
